Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Scotet

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Blood|July 7, 2012
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subsetChristelle Harly, Yves Guillaume, Steven Nedellec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2017
Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic PlasticityKristell Oizel, Cynthia Chauvin, Lisa Oliver, et al.
Cell Reports|July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cellsCarla E Cano, Christine Pasero, Aude De Gassart, et al.
Journal for Immunotherapy of Cancer|February 1, 2020
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytesLucine Marotte, Sylvain Simon, Virginie Vignard, et al.
Cell Reports|May 24, 2016
RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell ReceptorZsolt Sebestyen, Wouter Scheper, Anna Vyborova, et al.
Immunology and Cell Biology|March 31, 2017
Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8<sup>+</sup> T cellsHung-Chang Chen, Noémie Joalland, John S Bridgeman, et al.
Plos One|September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigenRona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
American Journal of Hematology|January 2, 2024
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamideMaxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, et al.
Science Translational Medicine|October 20, 2021
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune responseAude De Gassart, Kieu-Suong Le, Patrick Brune, et al.
Cell Death & Disease|January 8, 2020
Identification of a transient state during the acquisition of temozolomide resistance in glioblastomaMarion Rabé, Solenne Dumont, Arturo Álvarez-Arenas, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Blood|July 7, 2012
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subsetChristelle Harly, Yves Guillaume, Steven Nedellec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2017
Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic PlasticityKristell Oizel, Cynthia Chauvin, Lisa Oliver, et al.
Cell Reports|July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cellsCarla E Cano, Christine Pasero, Aude De Gassart, et al.
Journal for Immunotherapy of Cancer|February 1, 2020
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytesLucine Marotte, Sylvain Simon, Virginie Vignard, et al.
Cell Reports|May 24, 2016
RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell ReceptorZsolt Sebestyen, Wouter Scheper, Anna Vyborova, et al.
Immunology and Cell Biology|March 31, 2017
Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8<sup>+</sup> T cellsHung-Chang Chen, Noémie Joalland, John S Bridgeman, et al.
Plos One|September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigenRona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
American Journal of Hematology|January 2, 2024
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamideMaxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, et al.
Science Translational Medicine|October 20, 2021
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune responseAude De Gassart, Kieu-Suong Le, Patrick Brune, et al.
Cell Death & Disease|January 8, 2020
Identification of a transient state during the acquisition of temozolomide resistance in glioblastomaMarion Rabé, Solenne Dumont, Arturo Álvarez-Arenas, et al.
Pageof 7